Skip to main content
Premium Trial:

Request an Annual Quote

Another Player Joins the Fray

Is there room for another personal genomics company? That's the question Daniel MacArthur asks on the news that Australia-based Lumigenix recently launched and will offer its genetic test for $470, slightly more than competitor 23andMe. The biggest obstacles, he writes, are its second-to-market status and the anti-genetic testing climate in Australia. While some experts are optimistic that in the future consumer choice will be favored, MacArthur thinks it's a wait-and-see game. "It remains to be seen whether this venture will succeed in the face of rigorous competition, over-zealous regulation, and an economic slowdown that will likely seriously punish sales of 'luxury' goods like genome scans -- but I'd say the odds aren't good."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.